NPM1 and acute myeloid leukemia: All the subtypes of AMLs with high levels of endogenous FTO expression, such as those carrying t(11q23), t(15;17), NPM1 mutations, and/or FLT3-ITD, are more sensitive to ATRA treatment than the other AML subtypes [52].